A Brief Review: Biologics in the Treatment of Rheumatoid Arthritis

Anubhav Singh Chauhan[1], Vipul Sharma[1], Gopavaram Sumanth[2*], Pooja Prakash Atpadkar[2]

[1]Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) – Raebareli, Uttar Pradesh, India

[2]Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) – Raebareli, Uttar Pradesh, India

*Corresponding author: sumanth925@gmail.com

ABSTRACT - Rheumatoid joint inflammation (RA) is an ongoing fiery sickness, happens because of the irritation of the synovial liquid in the different joints. A kindled synovial layer discharges cytokines, which harms the joint-segment, for example, ligament, it prompts joint devastation. The ordinary medications utilized for treating RA are known as disease-modifying antirheumatic drugs (DMARDs). The conventional DMARDs have restricted use because of their results and additionally the restricted viability for treating RA. A few novel biologics have been presented for the treatment of RA: anakinra (Anti interleukin-1 (IL-1)), infliximab, adalimumab and etanercept (tumor necrosis factor (TNF) antagonists), rituximab (hostile to CD20 specialist), abatacept (particular T-cell modulator), and tocilizumab (IL-6). This audit gives the data about the RA, pathophysiology, and part of biologics in the treatment of RA.

Keywords: Biologics, rheumatoid arthritis, pathogenesis, anti-TNF agents.

1. INTRODUCTION

A biological medication (biologics) is a product containing components of living organisms from living organisms. They are standardized in compliance with the same pharmaceutical consistency, safety, and efficacy requirements as all biological drugs [1]. Biologicals are typically proteins gotten from a living being in cell culture as opposed to ordinary medications, which are made by compound blend. Their sub-molecular weight is higher by a factor of up to 1000 contrasted and customary medications. Therapeutic use incorporates immune system infections like rheumatoid joint pain, psoriasis, psoriatic joint pain, spondyloarthritis, constant incendiary inside sicknesses, and malignant growth. Biological drugs have gotten progressively significant in the treatment of rheumatic illnesses. Adalimumab, etanercept, and infliximab were among the best four smash-hit drugs in 2013 [2]. Biologic agents are propitious drug molecules targeting specific inflammatory meditators involved in various inflammation processes [3]. Concerning insulin, patents have recently expired or will expire relatively soon for many of the licensed insulin formulations[4]. For some biologics, the recent or imminent expiry of patents has led to the manufacture of biosimilar products. The increasing number of biosimilar drugs provides healthcare professionals and manufacturers with even more choices and also increases cost control, partially by moving from the originator to biosimilar alternatives [5]. In recent years, the demand for highly advanced and expensive biosimilars has made it much easier to treat high-burden diseases such as autoimmune diseases, tumors, and chronic renal failure.

2. RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a lifelong autoimmune inflammatory disease that occurs in women quite frequently than that in men and is generally attacking older people [6]. RA can cause cumulative incapacitation, premature death, and socioeconomic burdens as coating of the synovium is primarily affected. The clinical sign and symptoms include joint Inflexibility, swelling, redness, and even constraining the spectrum of kineticism [7-9]. Incendiary cytokines like TNF-α, IL-1, IL-6, CD20 and, CD80 are fundamental atomic focuses in rheumatology. Organic medications like mAb infliximab, adalimumab, golimumab, and certolizumab (coordinated against TNF-α, separately), just as belimumab, a B-cells improving specialist focus on these designs. Medication like tocilizumab, which ties to IL-6-receptor, the counter CD20 immune response rituximab, and the recombinant IL-1-receptor adversary anakinra are endorsed drugs in RA. Combination proteins or illusory protein are connected either to the extracellular ligand-restricting area of the human TNF-receptor (etanercept) or the extracellular space of CTLA4, a receptor restricting both to CD20 and CD80 (abatacept). Affirmed assignments in rheumatology, contingent upon the substance, are rheumatoid arthritis (RA), spondyloarthritis (SA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) [10].

3. PATHOGENESIS OF RA

RA is mainly a disease of continuous biological activation, which contributes to immune complexes in organs where it exhbitis effect. The clinical characteristics of this condition include synovial layer inflammation and joint degradation and imperious RA pathogenesis in fibroblast-like synoviocytes [11]. B-cells play an vital role in human immunity in a worldly condition, but in the case of RA, they are one of the causes of RA induction [12]. The autoreactive mature, naive B-cells are enormous in RA patients. As previous studies indicate, untreated RA patients show 3 to 4 times higher self-reactive B cells than non-RA patients in the peripheral blood [13]. The synovium in RA is acquired by immune components which include monocytes, dendritic cells, mast cells, Th1 (T helper 1), Th17 (T helper 17), B cells, and plasma cells. Cytokines like TNF-Alpha, IL-6triggers endothelial cells and magnetize immune cells to the synovial chamber which leads to inflammation [14]. The early of the last years in an characteristic of RA detection was anti-citrullinated protein antibodies (ACPA). ACPA is a group of antibodies with different isotypes utilization (i.e, IgG, IgA) that apperceives the non-essential amino acid citrulline in proteins. Citrulline is composed as effect of post-translational change of arginine, which is activated by intracellular enzymes [15]. The condition continues by forming granulation tissue at the synovial coating, pannus with generous angiogenesis and chemicals causing tissue devastation [16]. The fibroblast-like synoviocytes have a basic part in this pathogenic action [17]. Synovium buildup, ligament and bone tissue corruption, and joint degeneration with raised measure of calprotectin filling in as the biomarker of these events [18]. Cytokines draw in and gather resistant parts like initiated T-and B cells, monocytes, and macrophages from actuated fibroblast-like synoviocytes, in the joint territory. By motioning through TNF, they ineluctably trigger osteoclast which prompts bone debasement [19,20].



Figure 1: pathogenesis of rheumatoid arthritis

4. TNF INHIBITORS

4.1 Etanercept

Etanercept is TNF receptor antagonist drug that is accepted for the treatment of RA in adult patients with mild-to-severe symptoms [21]. The primary mechanism of etanercept is to inhibit TNF-receptors and thus avoiding the activation of critical inflammatory pathway [22,23].

4.2 Infliximab

Infliximab is a monoclonal antibody. It's presently being used for the treatment of various autoimmune disorders inculding rheumatoid arthritis [24]. Infliximab is a therapeutic approach that block TNF-Alpha receptor. This TNF-alpha blockage prevents the stimulation of the inflammatory pathway, and alleviates disease symptoms [25].

4.3 Adalimumab

Adalimumab is a recombinant, completely human IgG1 monoclonal antibody which cannot be structurally and functionally distinguished from natural human IgG1 [26]. Adalimumab attaches to TNF receptors and prevents the release of inflammatory mediators by obstructing their contact with p55 and p75 TNF cell surface receptors [27].

4.4 Golimumab

Golimumab is a human monoclonal antibody that aims at TNF-alpha in our body and prevents the release of inflammatory congitators. It targets both the transmembrane and soluble forms of human TNF, ensuing in stable more affinity complexes and stopping the attachment of TNF to its receptors. It is also given subcutaneously for the treatment of arthritis [28,29].

3.5 Certolizumab Pegol

Certolizumab pegol is a new inhibitor of TNF-alpha receptors which inhibits the inflammatory cascade in the autoimmune disorders [30]. The certolizumab Fab' was subsequently PEGylated via the site-categorical annexation of a 40kilo Dalton polyethylene glycol (PEG) moiety. Certolizumab pegol affixes and counteracts both soluble and transmembrane TNFα and obstructs the signaling through both the p55 and p75 TNFα receptors in vitro[31,32].

5. MODE OF ACTION OF TNF INHIBITORS

The activity of multiple cell types produced by various non-identical cell types in the body is affected by TNFα. The primary TNF producers are cells such as macrophages, astroglia, microglia, Langerhans cells, Kupffer cells, and alveolar macrophages [33] TNF alpha works via two transmembrane receptors: TNFR1, additionally known as p55 or p60, and TNFR2, additionally known as p75 or p80. TNF alpha binding to TNFR1 is considered to be a non-reversible process, whereas TNF alpha binding to TNF receptor 2 is kinetic both on and off. Therefore, it was suggested that TNFR2 could function in some cells as a "ligand passer" to TNFR1, increasing the local TNF alpha concentration at the cell surface through expeditious ligand attachment and separation [34]. TNF alpha is an vigorous pro-inflammatory agent that has been exposed to be one of the most profuse initial mediators in swollen tissue after trauma, infection or contact to bacterial derived lipopolysaccharide [35]. So the TNF alpha was measured to be a "master controller" of the generation of pro-inflammatory cytokines [36]. TNF alpha also improves mediators of lipid signal transduction, such as prostaglandins and platelet-activating factor [37]. TNF alpha plays a crucial role in the production of several long-term inflammatory conditions [38].



Figure 2: Schematic design of anti-TNF agents

6. IL-1 & IL-6 INHIBITORS

6.1 Anakinra

Anakinra is a protein that varies from another IL-6 receptor antagonist due to the presence of one methionine at N-terminus[42]. Anakinra is a drug molecule that comes under the class of IL-1 receptor antagonist and is used to alleviate the signs and symptoms of RA and other malignant disorders. It is a recombinant and marginally modified version of the human anti-IL-1 receptor protein[39]. It is administered as an SC injection and deleterious signs primarily include reactions such as flare at the site of injection, other infections, and other areas of concern include possible risk of malignancy [40,41].

6.2 Tocilizumab

Tocilizumab (TCZ) is a biological disease-modifying antirheumatic drug (DMARD) that targets IL-6 receptors and blocks signaling from them, prevents IL-6 from attacking both mIL-6R and sIL-6R, thereby obstructive the pro-inflammatory effects of IL-6 [43]. It binds to sIL-6R in a dose-reliant on manner and saturates the receptor [44].IL-6 has been verified as one of the first proinflammatory cytokines implicated in the development of RA hence use of IL-6 blockers in the very early phases of the disease could be very effective [45].

6.3 Olokizumab

Olokizumab (OKZ), comes under the category of monoclonal antibody, It targets the IL-6 cytokine receptor, and inhibits the final steps of the signaling pathway. OKZ greatly lessens the free IL-6 levels and C-reactive protein (CRP) [46]. Olokizumab is also used an emergence experimental cytokine storm COVID-19 complications treatment [47].

6.4 Sarilumab

Sarilumab binds with the IL-6 receptor prevents the inflammatory cascade, so patients are relieved of symptoms. Sarilumab is a human recombinant monoclonal antibody that belongs to the IL-6 receptor class of the antagonist [48].

7. CD-20, 80 & 86 INHIBITORS

7.1 Rituximab

Rituximab is a genetically modified Chimeric monoclonal anti-CD20 antibody that contains constant human IgG1Fc regions and small variable light and heavy chain regions from the IDEC-2B8 fragment of the anti-CD20 murine antibody, which is reactive to human CD20 [49]. Rituximab led to a rapid and complete depletion of all B-cells in peripheral blood. The level of B cell exhaustion in the fringe blood and synovium has been related decidedly with the clinical reaction of rituximab [55].

7.2 Abatacept

Abatacept is a recombinant fusion protein containing of the extracellular domain of human CTLA-4 and the altered Fc portion of human IgG1. T-cell activation is selectively impeded by abatacept by binding with CD-80 and CD-86 molecule. Inhibition of the T-Cell activation via a CD80/CD86 pathway has the potential, to modulate various types of inflammatory arbitrators involved in rheumatoid arthritis. Abatacept has been approved for the medication of highly aggressive and advanced RA in patients not before treated with methotrexate[50,51].

8. MANUFACTURING STEPS IN BIOLOGICS [54]



Figure 3: Steps involved in manufacturing of biologics

RECENT UPDATES OF BIOLOGICS IN COVID-19

The adequacy of interleukin-6 receptor antagonists in censoriously sick patients with Covid sickness 2019 (Covid-19) is uncertain. Tocilizumab and sarilumab both met the pre-characterized triggers for viability. In critically sick patients with Covid-19 getting organ uphold, therapy with anti-IL-6 agents, sarilumab and tocilizumab upgraded results including endurance. Every single Auxillary result and assessment maintained the viability of these anti IL-6 agents [52,53].

CONCLUSION

Biologic experts are as of now the fastest emerging fragment of medicine utilization. Not at all like artificially made minimal sub-molecular medications, biologics are more complexing, therapeutic things created by a living creature. They have become part of the standard of care in the treatment of an enormous variety of sicknesses, for instance, growth disorders, autoimmune infections, cardiovascular sicknesses, hemophilia, and remarkable inherited conditions. The issues of developing people and the connected extension in the inescapability of ongoing diseases include extraordinary concernover the world. Biologics are productive in the treatment of various dangerous chronic conditions.

ACKNOWLEDGEMENT

The authors wish the department of Pharmacology of NIPER for encouraging the data collection.

CONFLICTS OF INTERESTS

Authors do not have any conflicts of interest with the publication of the manuscript.

REFERENCES

[1] "Biosimilar medicines: Overview". European Medicines Agency (EMA). Retrieved 21 April 2020.
[2] Evaluate Pharma 2014, World Preview 2014, Outlook to 2020.
[3] Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34:365–374.
[4] Rotenstein LS, Ran N, Shivers JP, Yarchoan M, Close KL. Opportunities and Challenges for Biosimilars: what's on the horizon in the global insulin market? Clin Diabetes 2012;30:138–150.
[5] Braun Jürgen, Kudrin Alex. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals2016;44.257e266.
[6] Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl. 3): S265–S272.
[7] Van der Linden MP, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010; 62:3537–3546.
[8] Moura CS, et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res. Ther. 2015; 17:197.
[9] Cho, S. K. et al. Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean J. Intern. Med.2017;113.
[10] Nam JL, Ramiro S, Gaujoux-Viala C et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update for the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 2014;73(3):516–528.
[11] Nygaard G, Firestein GS. "Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes". Nature Reviews. Rheumatology. 2020;16 (6): 316–333.
[12] Bugatti S., Vitolo B., Caporali R., Montecucco C., Manzo A. B cells in rheumatoid arthritis: From pathogenic players to disease biomarkers. BioMed Res. Int. 2014; 2014:681-678.
[13] Samuels J., Ng Y.S., Coupillaud C., Paget D., Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 2005; 201:1659–1667.
[14] López-Mejías R, Carmona FD, Genre F, Remuzgo-Martínez S, González-Juanatey C, Corrales A, Identification of a 3'-Untranslated Genetic Variant of RARB Associated with Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. Arthritis Rheumatol. 2019 Mar;71(3):351-360.
[15] Wang S1, Wang Y. Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. BiochimBiophysActa. 2013; 1829:1126–1135.
[16] Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S (October 2015). "The pathogenic role of angiogenesis in rheumatoid arthritis". Angiogenesis. 18 (4): 433–48.
[17] Nygaard G, Firestein GS. "Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes". Nature Reviews. Rheumatology. 2020;16(6): 316–333.
[18] Abildtrup M, Kingsley GH, Scott DL. "Calprotectin as a biomarker for rheumatoid arthritis: a systematic review". The Journal of Rheumatology. 2015;42(5):760–70.
[19] Smolen JS, Aletaha D, McInnes IB. "Rheumatoid arthritis" (PDF). Lancet. 2016;388 (10055):2023–2038.
[20] Chiu YG, Ritchlin CT . "Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis". Expert Opinion on Biological Therapy. 2017;17(1):119–128.
[21] Enbrel Summary of Product Characteristics. http://www. Ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/000262/WC500027361.pdf (3 October 2016, date last accessed).
[22] Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7(10):769-79.
[23] Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. PharmacolTher. 2008 Feb;117(2):244-79.
[24] Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J PediatrGastroenterolNutr. 2014 Dec;59(6):758-62.
[25] Scott FI, Lichtenstein GR. Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterology. 2014;12(1):59-75.
[26] Salfield J, Kaymakcalan J, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. 1998;41(9):S57-S.
[27] Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult Patients with rheumatoid arthritis. BioDrugs. 2006;20(5):293–311.
[28] Chovel-Sella A, Karplus R, Sella T, Amital H. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. Isr Med Assoc J. 2012;14:390–394.
[29] Kay J, Rahman MU. Golimumab: a novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid.
[30] Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. MolInterv. 2003;3:310–318.

[31] Nesbitt A, Fossati G, Bergin M Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumour necrosis factor α agents. Inflamm Bowel Dis. 2007;13:1323–1332.
[32] Gramlick G, Fossati G, Nesbitt A, Henry AJ. Neutralization of soluble and membrane tumour necrosis factor α by infliximab, adalimumab or certolizumab pegol using p55 or p75 TNFα receptor bioassay. Gastroenterology. 2006;130:697.
[33] Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW. Mice deficient for the 55 kdtumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457–467.
[34] Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. J Biol Chem. 1993;268(25):18542–18548.
[35] Feldmann M, Brennan FM, Elliott M, Katsikis P, Maini RN. TNF alpha as a therapeutic target in rheumatoid arthritis. Circ Shock. 1994;43(4):179–184.
[36] Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA) Clin Exp Immunol. 1995;101(2):207–212.
[37] Vassalli P. The pathophysiology of Tumor necrosis factors. Annu Rev Immunol. 1992; 10:411–452.
[38] Takada Y, Aggarwal BB. Evidence that genetic deletion of the TNF receptor p60 or p80 in macrophages modulates RANKL-induced signalling. Blood. 2004;104(13):4113–4121.
[39] UK Anakinra label". UK Electronic Medicines Compendium. 5 October 2017. Retrieved 23 March 2018.
[40] FDA. Kineret (anakinra) physician packet insert: Kineret (anakinra) prescribing information. Rockville, MD: U.S. Food and Drug Administration; 2001. [Internet. Accessed March 19, 2009.]
[41] American College of Rheumatology subcommittee on rheumatoid arthritis Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328–46.
[42] "US Anakinra label" (PDF). FDA. May 2016. Retrieved 23 March 2018. For label updates see FDA index page for BLA 103950.
[43] Yoshio-Hoshino N, Adachi Y, Aoki C, et al. Establishment of a New interleukin-6 (IL-6) receptor inhibitor applicable to the gene Therapy for IL-6-dependent tumor. Cancer Res. 2007;67(3):871-5.
[44] Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibitsSignal transduction mediated by both mIL-6R and sIL-6R, but notBy the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–40.
[45] Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52(11):3460–3469.
[46] Fleischmann R, Kivitz AJ, Wagner F, et al. A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab,an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2011;70(Suppl 3):471.
[47] Hickling M, Golor G, Jullion A, et al. Safety and pharmacokinetics of CDP6038, an Anti-IL-6 monoclonal antibody, administered by subcutaneous injection and Intravenous infusion to healthy male volunteers: a phase 1 study. Ann Rheum Dis 2011;70(Suppl 3):471
[48] Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015; 67:1424–37.
[49] McLaughlin P, Grillo-Lopez AJ, Link BK, Czuczman MS, Williams ME, Heyman MR, et al. Rituximab chimeric anti-CD20 monoclonal antibody Therapy for relapsed indolent lymphoma: half of patients respond to aFour-dose treatment program. J Clin Oncol 1998;16:2825–33
[50] European Medicines Agency. Orencia (abatacept): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 1 June 2017.
[51] Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162–6.
[52] Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5
[53] Gremese E, Cingolani A, Boselio SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EclinicalMedicine 2020;27:100553.
[54] Sahoo N, Choudhury K, Manchikanti P. Manufacturing of biodrugs:need for harmonization in regulatory standards.Biodrugs. 2009;23:217-229.
[55] Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917–925.